The condition tends to run in families and is more common among women
Funding Financial support was obtained from the Regione Toscana Bando FAS Salute 2014 (Italy) in the framework of the project CapsuLight Design of an ingestible robotic pill based on LED sources for the treatment of gastrointestinal disorders (CUP B52I14005760002)
Side Effects Across Different Dosage Levels Side effects typically intensify with each dose increase, though the pattern varies significantly between individuals: Starter Doses (Wegovy 0.25-0.5mg, Zepbound 2.5-5mg) Common: Mild nausea, reduced appetite, occasional constipation Less common: Mild heartburn, slight fatigue Rare at this stage: Severe vomiting, intense gastrointestinal distress Middle Doses (Wegovy 1-1.7mg, Zepbound 7.5-10mg) Common: Moderate nausea (often worse after meals), constipation, occasional vomiting, delayed gastric emptying (feeling full longer) Less common: Headaches, fatigue, sulfur burps, acid reflux Rare but reported: Hair thinning (typically temporary), gallbladder issues Maintenance Doses (Wegovy 2.4mg, Zepbound 12.5-15mg) Common: All of the above, potentially more pronounced Additional concerns: Muscle loss if protein intake isn't adequate Long-term considerations: Nutritional deficiencies due to reduced food intake, delayed gastric emptying Tolerance Development: Does the Effect Diminish Over Time
24 godzin, potem naley zdj
However, the incidence of obstructive sleep apnea was lower in the AOM cohort (3.12%) than the non-AOM cohort (12.56%
These variations are generally considered normal adaptations to the medication's effects on digestive transit
